Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Non-insulin pharmacological therapies for treating type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exenatide: pharmacokinetics, clinical use, and future directions

    Research output: Contribution to journalReviewResearchpeer-review

  3. Management of cardiovascular disease in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of interest as adjunct therapies to insulin. Areas covered: In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D. Expert opinion: The current evidence shows that the efficacy of non-insulin therapies as add-on therapies to insulin is minimal or modest with an average HbA1c reduction of 0.2-0.5% (2-6 mmol/mol). Indeed, the current focus is on the development of SGLT inhibitors as adjuncts to insulin in type 1 diabetes. Studies of subgroups with obesity, residual beta-cell function (including newly diagnosed patients) and patients prone to hypoglycemia could be areas of future research.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number9
Pages (from-to)947-960
Number of pages14
ISSN1465-6566
DOIs
Publication statusPublished - Jun 2018

ID: 54760002